Association of CSF Proteome with CSF P‐tau181 levels and other biomarkers of Alzheimer's Disease.

Background: We investigated the relationship between the cerebrospinal fluid (CSF) proteome in Alzheimer’s disease (AD) and the clinical and biomarker‐assisted diagnoses.

Methods: CSF was collected in 500 individuals of non‐Hispanic white, African Americans, and Caribbean Hispanic individuals from Dominican Republic and New York City. CSF biomarkers of AD were measured including P‐tau181, Aβ40, Aβ42, total‐tau, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP).

Multi‐omics integration in Caribbean Hispanics identifies cardio and cerebrovascular pathways in AD.

Background: Multi‐omics integration can clarify molecular mechanisms contributing to Alzheimer’s Disease (AD). We conducted a quantitative trait locus (QTL) analysis across three omics layers to identify genetic variants that regulate metabolomics, gene expression, and DNA methylation in AD.

Method: We analyzed data from Caribbean Hispanic individuals from the Dominican Republic and New York with AD or family history of AD including: N = 750 with whole genome sequencing (WGS), RNA‐sequencing, and DNA methylation (in blood), and N = 272 with untargeted metabolomics.

Data-Independent Acquisition and Label-Free Quantification for Quantitative Proteomics Analysis of Human Cerebrospinal Fluid.

This article presents a practical guide to mass spectrometry-based data-independent acquisition and label-free quantification for proteomics analysis applied to cerebrospinal fluid, offering a robust and scalable approach to probing the proteomic composition of the central nervous system. © 2024 Wiley Periodicals LLC. Basic Protocol 1: Cerebrospinal fluid sample collection and preparation for mass spectrometry analysis Basic Protocol 2: Mass spectrometry sample analysis with data-independent acquisition Support Protocol: Data-dependent mass spectrometry and spectral library construction Basic Protocol 3: Analysis of mass spectrometry data.